Ambros Therapeutics moved to the public markets via a reverse merger with Werewolf Therapeutics, combining development resources behind a Phase 3 pain drug intended for pain types unresponsive to currently available options. The transaction includes a $150 million private placement, aligning financing with a late-stage clinical push. At the same time, Werewolf’s reverse-merger path to Ambros mirrors a broader strategy for late-stage biotechs to lock funding through structured corporate moves when traditional IPO windows are less predictable. For investors and competitors, the deal highlights how rare disease and pain programs continue to be financed through alternative capital-raising mechanisms tied to near-term clinical milestones.